24,546 Shares in Accelerate Diagnostics Inc (AXDX) Acquired by SeaCrest Wealth Management LLC
SeaCrest Wealth Management LLC purchased a new position in Accelerate Diagnostics Inc (NASDAQ:AXDX) during the 4th quarter, HoldingsChannel reports. The firm purchased 24,546 shares of the medical research company’s stock, valued at approximately $643,000.
Other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc boosted its stake in Accelerate Diagnostics by 31.7% during the 2nd quarter. Legal & General Group Plc now owns 6,748 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 1,625 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at $243,000. Intl Fcstone Inc. purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at $322,000. Mutual of America Capital Management LLC purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at $332,000. Finally, Voya Investment Management LLC boosted its stake in Accelerate Diagnostics by 13.9% during the 2nd quarter. Voya Investment Management LLC now owns 12,193 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 1,486 shares during the last quarter. Institutional investors own 47.77% of the company’s stock.
Several research firms have recently weighed in on AXDX. BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call. ValuEngine raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Friday. Finally, Zacks Investment Research raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $33.00.
In other news, Director Jack W. Schuler purchased 20,000 shares of the stock in a transaction dated Monday, November 13th. The shares were purchased at an average cost of $18.98 per share, with a total value of $379,600.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jack W. Schuler purchased 5,500 shares of the stock in a transaction dated Friday, November 17th. The shares were purchased at an average cost of $22.00 per share, for a total transaction of $121,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 146,681 shares of company stock worth $2,779,149 over the last three months. Insiders own 50.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/02/06/24546-shares-in-accelerate-diagnostics-inc-axdx-acquired-by-seacrest-wealth-management-llc.html.
Accelerate Diagnostics Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.